Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Amyloid Precursor Protein Secretases
Benzazepines
Disease-Free Survival
Enzyme Inhibitors
Female
Humans
Male
Melanoma
Middle Aged
Neoplasm Metastasis
Receptors, Notch
Survival Rate
T-Lymphocytes
authors with profiles
Thomas F. Gajewski